SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Dollar and Under Sleeper Stocks

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ga Bard who wrote (4375)2/9/1998 12:28:00 PM
From: Israel  Read Replies (2) of 8835
 
SYBD news, currently .145 X .15 on 189700K shares..

Synthetic Blood International Announces Fluorovent Patent Approval

KETTERING, Ohio--(BUSINESS WIRE)--Feb. 9, 1998--Synthetic Blood International Inc. (SYBD) (OTC/BB:SYBD) Monday announced that it has received a notice of allowance from the U.S. Patent Office for 30 claims in its second Fluorovent patent filed by Leland C. Clark Jr., Ph.D., vice president of research and development.

The company expects the patent to be issued in approximately 90 days.

This patent application covers methods of assisting breathing in adults and children with lung disorders without mechanical assistance. It is an extension of the original patent issued last October for new perfluorocarbons that coat the lung surface to enhance the oxygen/ carbon dioxide.

Our laboratory studies have shown that Fluorovent significantly assists ambient gas exchange in mammals without resulting in hyperinflated lung syndrome. This product can be used to treat pulmonary disorders and may be used without mechanical assistance. As a result, patients with acute respiratory disorders may become mobile and move with less effort as a result of this improvement in gas exchange,'' said Roger A. Ekbom, chief executive officer.

SYBD is located in Kettering. The company's stock is traded on the OTC Electronic Bulletin board under the symbol SYBD.

CONTACT:

Synthetic Blood International Inc., Kettering

Gerald D. Schlater, 800/809-6054

KEYWORD: OHIO

BW0147 FEB 09,1998
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext